<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01582048</url>
  </required_header>
  <id_info>
    <org_study_id>E:531/2011</org_study_id>
    <secondary_id>2011-002192-41</secondary_id>
    <nct_id>NCT01582048</nct_id>
  </id_info>
  <brief_title>Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning</brief_title>
  <official_title>Multicenter Phase II Study of Peritransplantation Immunosuppression Using ATG, Rituximab, Sirolimus and Mycophenolate Mofetil in Patient Receiving Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning With Fludarabine and Treosulfan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Wolfgang Bethge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Neovii Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility and toxicity of peritransplantation immunosuppression with ATG, sirolimus,
      mycophenolate mofetil and rituximab in patients receiving mismatched allogeneic HCT after a
      reduced intensity conditioning regimen with fludarabine/treosulfan
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow enrollment
  </why_stopped>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">August 17, 2016</completion_date>
  <primary_completion_date type="Actual">August 17, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>12 months after HCT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>24 months after HCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity according CTC of protocol on day 100</measure>
    <time_frame>on day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment on day 100</measure>
    <time_frame>on day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft versus host disease</measure>
    <time_frame>3 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>2 years after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution of CD3, CD3/CD4/CD8, CD56, CD19 cells</measure>
    <time_frame>3 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft versus host disease</measure>
    <time_frame>6 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>24 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response</measure>
    <time_frame>12 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response</measure>
    <time_frame>24 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution of CD3, CD3/CD4/CD8, CD56, CD19 cells</measure>
    <time_frame>6 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution of CD3, CD3/CD4/CD8, CD56, CD19 cells</measure>
    <time_frame>12 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution of CD3, CD3/CD4/CD8, CD56, CD19 cells</measure>
    <time_frame>24 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft versus host disease</measure>
    <time_frame>12 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft versus host disease</measure>
    <time_frame>24 months after HCT</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Patients Receiving Mismatched Allogeneic HCT</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>immunosuppression</intervention_name>
    <description>Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for mismatched allogeneic HCT

          -  Unrelated donor with maximal 2 antigen or allelic mismatches in HLA-I or HLA-II

          -  Age &gt;=75, &gt;=18 years

          -  Patients Age &lt;=50 if a HCT-CI score &gt; 2 [acc. to Sorror et al., 2005]

          -  Karnofsky Index &gt;60%

          -  Patients with:

               -  Acute myeloid leukemia in CR (&lt;5% blasts)

               -  Acute lymphoblastic leukemia in CR (&lt; 5% blasts)

               -  Myelodysplastic syndrome with up to 20% blasts

               -  Osteomyelofibrosis

               -  Chronic lymphocytic leukemia

               -  High grade Non-Hodgkin Lymphoma in CR or PR

               -  Low grad Non-Hodgkin Lymphoma in CR or PR

               -  M. Hodgkin in CR or PR

               -  Chronic myeloid leukaemia in chronic phase or CR of blast crisis

        Exclusion Criteria:

          -  Patients with &gt;5% blasts in BM at the time of transplantation

          -  Progressive or chemorefractory disease

          -  Less than 3 months after preceding HCT

          -  CNS involvement with disease

          -  Fungal infections with radiological progression after receipt of amphotericin B or
             active triazole for greater than 1 month.

          -  Liver function abnormalities with bilirubin &gt;2 mg/dL and elevation of transaminases
             higher 2x upper limit of normal.

          -  Chronic active viral hepatitis

          -  Ejection fraction &lt;40 % on echocardiography

          -  Patients with &gt; grade II hypertension by CTC criteria

          -  Creatinine clearance &lt;50 ml/min

          -  Proteinuria &gt;800 mg/24 h

          -  Respiratory failure necessitating supplemental oxygen or DLCO &lt;30%

          -  Allergy against murine antibodies

          -  Known allergy/intolerance against sirolimus or one of it's excipients

          -  HIV-Infection

          -  Female patients who are pregnant or breast feeding, or adults of reproductive
             potential not employing an effective method of birth control during study treatment
             and for at least 12 months thereafter. (Women of childbearing potential must have a
             negative serum pregnancy test at study entry)

          -  Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes,
             congestive heart failure, myocardial infarction within 6 months prior to the study,
             unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled
             infection) which could compromise participation in the study

          -  Patients with a history of psychiatric illness or condition which could interfere with
             their ability to understand the requirements of the study (this includes
             alcoholism/drug addiction)

          -  Patients unwilling or unable to comply with the protocol

          -  Unable to give informed consent

          -  Enrollment in an other trial interfering with the endpoints of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang A Bethge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center University Hospital of Tuebingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematology/Oncology Medical Center University Hospital of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bone Marrow Transplantation Unit Medical Center University Hospital of Nuernberg</name>
      <address>
        <city>Nuernberg</city>
        <zip>D-90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology/Oncology Medical Center University Hospital of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BMT-Unit Deutsche Klinik für Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Wolfgang Bethge</investigator_full_name>
    <investigator_title>Associate Professor Hematology/Oncology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

